Archer Aviation (ACHR) 10-Q12 May 222022 Q1 Quarterly reportFinancial data

Company Profile

Cover

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2022	May 06, 2022
Entity Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-39668
Entity Registrant Name	Archer Aviation Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	85-2730902
Entity Address, Address Line One	1880 Embarcadero Road
Entity Address, City or Town	Palo Alto
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94303
City Area Code	650
Local Phone Number	272-3233
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Central Index Key	0001824502
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Common Class A
Entity Information [Line Items]
Title of 12(b) Security	Class A Common Stock, par value $0.0001 per share
Trading Symbol	ACHR
Security Exchange Name	NYSE
Entity Common Stock, Shares Outstanding		169,477,724
Warrants
Entity Information [Line Items]
Title of 12(b) Security	Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share
Trading Symbol	ACHR WS
Security Exchange Name	NYSE
Common Class B
Entity Information [Line Items]
Entity Common Stock, Shares Outstanding		70,951,345

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 704.2	$ 746.6
Restricted cash	2.9	0.3
Prepaid expenses	9.3	7.6
Other current assets	0.4	0.3
Total current assets	716.8	754.8
Property and equipment, net	5.9	5.9
Intangible assets, net	0.4	0.5
Right-of-use assets	12.7	4.5
Other long-term assets	2.1	2.7
Total assets	737.9	768.4
Current liabilities
Accounts payable	1.8	3.4
Current portion of lease liabilities	3.6	3.1
Current portion of notes payable	9.5	9.5
Accrued expenses and other current liabilities	19.4	12.3
Total current liabilities	34.3	28.3
Notes payable, net of current portion	7	9.3
Lease liabilities, net of current portion	8.8	1.2
Warrant liabilities	23.8	30.3
Other long-term liabilities	0.3	0.4
Total liabilities	74.2	69.5
Commitments and contingencies
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of March 31, 2022 and December 31, 2021	0	0
Additional paid-in capital	1,096.5	1,072.5
Accumulated deficit	(432.8)	(373.6)
Total stockholders’ equity	663.7	698.9
Total liabilities and stockholders’ equity	737.9	768.4
Common Class A
Stockholders’ equity
Common stock, value, issued	0	0
Common Class B
Stockholders’ equity
Common stock, value, issued	$ 0	$ 0

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, authorized (in shares)	10,000,000	10,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common Class A
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	700,000,000	700,000,000
Common stock, issued (in shares)	165,201,225	162,789,591
Common stock, outstanding (in shares)	165,201,225	162,789,591
Common Class B
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, authorized (in shares)	300,000,000	300,000,000
Common stock, issued (in shares)	73,579,586	74,937,945
Common stock, outstanding (in shares)	73,579,586	74,937,945

Consolidated Condensed Statemen

Consolidated Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses
Research and development	$ 27.5	$ 10.1
General and administrative	37.8	6.6
Other warrant expense	0	78.2
Total operating expenses	65.3	94.9
Loss from operations	(65.3)	(94.9)
Other income, net	6.5	0
Interest expense, net	(0.4)	0
Loss before income taxes	(59.2)	(94.9)
Net loss	(59.2)	(94.9)
Comprehensive loss	$ (59.2)	$ (94.9)
Net loss per share, basic (in dollars per share)	$ (0.25)	$ (1.70)
Net loss per share, diluted (in dollars per share)	$ (0.25)	$ (1.70)
Weighted-average shares outstanding, basic (in shares)	239,802,805	55,796,898
Weighted-average shares outstanding, diluted (in shares)	239,802,805	55,796,898

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Stockholders’ Equity - USD ($) $ in Millions	Total	Additional Paid-in Capital	Accumulated Deficit	Common Class ACommon Stock	Common Class BCommon Stock
Beginning balance (in shares) at Dec. 31, 2020				49,828,517	66,714,287
Beginning balance at Dec. 31, 2020	$ 35.9	$ 61.7	$ (25.8)	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options (in shares)				147,319	525,044
Exercise of stock options	0
Issuance of warrants and warrant expense	78.2	78.2
Stock-based compensation	0.9	0.9
Net loss	(94.9)		(94.9)
Ending balance (in shares) at Mar. 31, 2021				49,975,836	67,239,331
Ending balance at Mar. 31, 2021	20.1	140.8	(120.7)	$ 0	$ 0
Beginning balance (in shares) at Dec. 31, 2021				162,789,591	74,937,945
Beginning balance at Dec. 31, 2021	698.9	1,072.5	(373.6)	$ 0	$ 0
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of Class B to Class A common stock (in shares)				1,757,980	(1,757,980)
Conversion of Class B to Class A common stock	0
Issuance of restricted stock and restricted stock expense (in shares)				300,014
Issuance of restricted stock and restricted stock expense	$ 16	16
Exercise of stock options (in shares)	753,261			353,640	399,621
Exercise of stock options	$ 0.1	0.1
Issuance of warrants and warrant expense	1.2	1.2
Stock-based compensation	6.7	6.7
Net loss	(59.2)		(59.2)
Ending balance (in shares) at Mar. 31, 2022				165,201,225	73,579,586
Ending balance at Mar. 31, 2022	$ 663.7	$ 1,096.5	$ (432.8)	$ 0	$ 0

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (59.2)	$ (94.9)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	0.6	0.2
Debt discount and issuance cost amortization	0.2	0
Stock-based compensation	24.5	0.9
Change in fair value of warrant liabilities	(6.6)	0
Non-cash lease expense	0.9	0.3
Research and development warrant expense	1.2	0
Other warrant expense	0	78.2
Changes in operating assets and liabilities:
Prepaid expenses	(1.7)	0
Other current assets	(0.1)	(0.1)
Other long-term assets	0.6	0
Accounts payable	(1.6)	3.7
Accrued expenses and other current liabilities	5.3	0
Operating lease right-of-use assets and lease liabilities, net	(0.9)	(0.3)
Net cash used in operating activities	(36.8)	(12)
Cash flows from investing activities
Purchase of property and equipment	(0.6)	(1.1)
Net cash used in investing activities	(0.6)	(1.1)
Cash flows from financing activities
Repayment of long-term debt	(2.5)	0
Proceeds from exercise of stock options	0.1	0
Net cash used in financing activities	(2.4)	0
Net decrease in cash, cash equivalents, and restricted cash	(39.8)	(13.1)
Cash, cash equivalents, and restricted cash, beginning of period	746.9	36.6
Cash, cash equivalents, and restricted cash, end of period	707.1	23.5
Supplemental Cash Flow Information:
Cash paid for interest	0.3	0
Non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable	$ 0	$ 0.1

Organization and Nature of Busi

Organization and Nature of Business	3 Months Ended
Organization and Nature of Business	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	Organization and Nature of Business Organization and Nature of Business Archer Aviation Inc. (the “Company,” “we,” “us” or “our”), a Delaware corporation, with its headquarters located in Palo Alto, California, is an aerospace company. The Company’s mission is to advance the benefits of sustainable air mobility. The Company’s goal is to move people throughout the world’s cities in a quick, safe, sustainable, and cost-effective manner. To accomplish this goal, the Company is designing and developing an electric vertical takeoff and landing (“eVTOL”) aircraft for use in future urban air mobility (“UAM”) networks. The Company’s Planned Lines of Business Upon receipt of all necessary Federal Aviation Administration (“FAA”) certifications and any other government approvals necessary for the Company to manufacture and operate its aircraft, the Company intends to operate two complementary lines of business. The Company’s core focus is direct-to-consumer (“Archer UAM”) with its secondary focus being business-to-business (“Archer Direct”). Archer UAM The Company plans to operate its own UAM ecosystem initially in select major U.S. cities, such as Los Angeles and Miami. The Company’s UAM ecosystem will operate using its eVTOL aircraft, which is currently in development. Archer Direct The Company also plans to selectively sell a certain amount of its eVTOL aircraft to third parties. Business Combination On September 16, 2021 (the “Closing Date”), Archer Aviation Inc., a Delaware corporation (prior to the closing of the Business Combination (as defined below), “Legacy Archer”), Atlas Crest Investment Corp., a Delaware corporation (“Atlas”), and Artemis Acquisition Sub Inc., a Delaware corporation and a direct, wholly-owned subsidiary of Atlas (“Merger Sub”), consummated the closing of the transactions contemplated by the Business Combination Agreement, dated February 10, 2021, as amended and restated on July 29, 2021, by and among Atlas, Legacy Archer and Merger Sub (the “Business Combination Agreement”), following approval at a special meeting of the stockholders of Atlas held on September 14, 2021 (the “Special Meeting”). Unless otherwise specified or unless the context otherwise requires, references in these notes to Legacy Archer refer to Archer prior to the Business Combination and references in these notes to “New Archer” refer to Archer following the Business Combination. Pursuant to the terms of the Business Combination Agreement, a business combination of Legacy Archer and Atlas was effected by the merger of Merger Sub with and into Legacy Archer, with Legacy Archer surviving the merger (the “Surviving Entity”) as a wholly-owned subsidiary of Atlas (the “Merger,” and, collectively with the other transactions described in the Business Combination Agreement, the “Business Combination”). Following the consummation of the Merger on the Closing Date, the Surviving Entity changed its name from Archer Aviation Inc. to Archer Aviation Operating Corp., and Atlas changed its name from Atlas Crest Investment Corp. to Archer Aviation Inc. and it became the successor registrant with the U.S. Securities and Exchange Commission (the “SEC”). Prior to the closing of the Business Combination, the Class A common stock and public warrants of Atlas were listed on the New York Stock Exchange (“NYSE”) under the symbols “ACIC” and “ACIC WS,” respectively. New Archer Class A common stock and public warrants are currently listed on the NYSE under the symbols “ACHR” and “ACHR WS,” respectively. The financial statements included in this Quarterly Report on Form 10-Q reflect (i) the historical operating results of Legacy Archer prior to the Business Combination; (ii) the combined results of Atlas and Legacy Archer following the closing of the Business Combination; (iii) the assets and liabilities of Legacy Archer at their historical cost; and (iv) the Company’s equity structure for all periods presented. COVID-19 Pandemic In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The rapid spread of COVID-19 caused volatility and disruption in financial markets and prompted governments and businesses to take unprecedented measures such as travel restrictions, quarantines, shelter-in-place orders, and business shutdowns. The impact of the COVID-19 pandemic continues to evolve due to, among other reasons, the emergence of additional variants or strains of COVID-19. As such, the full magnitude of the pandemic’s effect on the Company’s financial condition, liquidity, and future results of operations is uncertain. Management continues to actively monitor the Company’s financial condition, liquidity, operations, suppliers, industry, and workforce, but currently does not anticipate any material impairments as a result of COVID-19 and will continue to evaluate the impact of COVID-19 on an ongoing basis.

Liquidity and Going Concern

Liquidity and Going Concern	3 Months Ended
Liquidity and Going Concern	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidation and Going Concern	Liquidity and Going Concern Since the Company’s formation, the Company has devoted substantial effort and capital resources to the design and development of its planned eVTOL aircraft and UAM network. Funding of these activities has primarily been through the net proceeds received from the issuance of related and third-party debt (Note 6), and the sale of preferred and common stock to related and third parties (Note 8). Through March 31, 2022, the Company has incurred cumulative losses from operations, negative cash flows from operating activities, and has an accumulated deficit of $432.8 million. Following the closing of the Business Combination on the Closing Date, the Company received net cash proceeds of $801.8 million. Additionally, the Company had cash and cash equivalents of $704.2 million as of March 31, 2022, which management believes will be sufficient to fund the Company’s current operating plan for at least the next 12 months from the date these consolidated condensed financial statements were issued. There can be no assurance that the Company will be successful in achieving its business plans, that the Company’s current capital will be sufficient to support its ongoing business plans, or that any additional financing will be available in a timely manner or on acceptable terms, if at all. If the Company’s business plans require it to raise additional capital, but the Company is unable to do so, it may be required to alter, or scale back its aircraft design, development and certification programs, as well as its manufacturing capabilities, or be unable to fund capital expenditures. Any such events would have a material adverse effect on the Company’s financial position, results of operations, cash flows, and ability to achieve the Company’s intended business plans.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited consolidated condensed financial statements have been prepared pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of financial position, results of operations, and cash flows for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. The unaudited consolidated condensed financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2021 set forth in the Company’s Annual Report on Form 10-K. The December 31, 2021 consolidated condensed balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. The Company has provided a discussion of significant accounting policies, estimates, and judgments in the Company’s audited consolidated financial statements. There have been no changes to the Company’s significant accounting policies since December 31, 2021 which are expected to have a material impact on the Company’s financial position, results of operations, or cash flows. Retroactive Application of Reverse Recapitalization The Business Combination was accounted for as a reverse recapitalization of equity structure. Pursuant to U.S. GAAP, the Company retrospectively recast its weighted-average outstanding shares within the Company’s consolidated condensed statement of operations and comprehensive loss for the three months ended March 31, 2021. As part of the closing, all of Legacy Archer’s issued Series Seed redeemable convertible preferred stock and Series A redeemable convertible preferred stock were converted into Legacy Archer common stock, which were converted again, along with all other issued and outstanding common stock of Legacy Archer, into New Archer Class A common stock and New Archer Class B common stock. The basic and diluted weighted-average Legacy Archer common stock were retroactively converted to New Archer Class A common stock and New Archer Class B common stock to conform to the recast in the consolidated condensed statements of stockholders’ equity. Cash, Cash Equivalents, and Restricted Cash Cash consists of cash on deposit with financial institutions. Cash equivalents consist of short-term, highly liquid financial instruments that are readily convertible to cash and have maturities of three months or less from the date of purchase. The Company’s cash and cash equivalents include money market funds of $0.3 million as of each of March 31, 2022 and December 31, 2021. Money market funds, which are considered cash equivalents, are recorded at fair value and classified as Level 1 within the fair value hierarchy. Restricted cash consists of cash held as security for the Company’s standby letters of credit to support three of the Company’s leased properties. Refer to Note 7 - Commitments and Contingencies for further details. The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the balance sheets that sum to amounts reported on the statements of cash flows: March 31, December 31, Cash and cash equivalents $ 704.2 $ 746.6 Restricted cash 2.9 0.3 Total cash, cash equivalents, and restricted cash $ 707.1 $ 746.9 Fair Value Measurements The Company applies the provisions of Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which defines a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurements. The provisions of ASC 820 relate to financial assets and liabilities as well as other assets and liabilities carried at fair value on a recurring and nonrecurring basis. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2 Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. The carrying amounts of the Company’s cash, accounts payable, accrued compensation, and accrued liabilities approximate fair value due to the short-term nature of these instruments. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Description Level March 31, December 31, (In millions) Assets: Money Market Funds 1 $ 0.3 $ 0.3 Liabilities: Warrant Liability – Public Warrants 1 $ 15.9 $ 20.2 Warrant Liability – Private Placement Warrants 3 $ 7.9 $ 10.1 Public Warrants The measurement of the public warrants as of March 31, 2022 is classified as Level 1 due to the use of an observable market quote in an active market under the ticker “ACHR WS.” The quoted price of the public warrants was $0.91 per warrant as of March 31, 2022. Private Placement Warrants The Company utilizes a Monte Carlo simulation model for the private placement warrants at each reporting period, with changes in fair value recognized in the statement of operations and comprehensive loss. The estimated fair value of the private placement warrant liability is determined using Level 3 inputs. Inherent in a binomial options pricing model and Monte Carlo simulation model are assumptions related to expected share-price volatility, expected life, risk-free interest rate, and dividend yield. The key inputs into the Monte Carlo simulation model for the private placement warrants are as follows: Input March 31, December 31, Stock price $ 4.81 $ 6.04 Strike price $ 11.50 $ 11.50 Dividend yield 0.00 % 0.00 % Term (in years) 4.46 4.71 Volatility 51.1 % 45.3 % Risk-free rate 2.43 % 1.22 % The following table presents the change in fair value of the Company’s Level 3 private placement warrants during the three months ended March 31, 2022 (in millions): Balance as of December 31, 2021 $ 10.1 Change in fair value (2.2) Balance as of March 31, 2022 $ 7.9 The Company recognized a gain in connection with changes in the fair value of warrant liabilities of $6.6 million within other income, net in the consolidated condensed statement of operations and comprehensive loss during the three months ended March 31, 2022. Refer to Note 12 - Liability Classified Warrants for additional information about the public and private placement warrants. Financial Instruments Not Recorded at Fair Value on a Recurring Basis Certain financial instruments, including debt, are not measured at fair value on a recurring basis in the balance sheets. The fair value of debt as of March 31, 2022 approximates its carrying value. Assets and Liabilities Recorded at Fair Value on a Non-Recurring Basis Certain assets and liabilities are subject to measurement at fair value on a non-recurring basis if there are indicators of impairment or if they are deemed to be impaired as a result of an impairment review. Intangible Assets, Net Intangible assets consist solely of domain names and are recorded at cost, net of accumulated amortization, and if applicable, impairment charges. Amortization of domain names is provided over a 15-year estimated useful life on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company has analyzed a variety of factors in light of the known impact to date of the COVID-19 pandemic on the Company’s business to determine if any circumstance could trigger an impairment loss, and, at this time and based on the information presently known, do not believe that it is more likely than not that an impairment loss has been incurred. As of March 31, 2022 and December 31, 2021, the net carrying amounts for domain names were $0.4 million and $0.5 million recorded in the Company’s consolidated condensed balance sheets, respectively. Net Loss Per Share Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. For all periods presented, the calculation of basic net loss per share excludes shares issued upon the early exercise of stock options where the vesting conditions have not been satisfied. Because the Company reported net losses for all periods presented, diluted loss per share is the same as basic loss per share. Contingently issuable shares, including equity awards with performance conditions, are considered outstanding common shares and included in basic net loss per share as of the date that all necessary conditions to earn the awards have been satisfied. Prior to the end of the contingency period, the number of contingently issuable shares included in diluted net loss per share is based on the number of shares, if any, that would be issuable under the terms of the arrangement at the end of the reporting period. Because the Company reported net losses for all periods presented, all potentially dilutive common stock equivalents are antidilutive and have been excluded from the calculation of net loss per share. The diluted net loss per common share was the same for Class A and Class B common shares because they are entitled to the same liquidation and dividend rights. The following table presents the number of antidilutive shares excluded from the calculation of diluted net loss per share: Three Months Ended March 31, 2022 2021 Options to purchase common stock 8,604,636 11,899,579 Unvested restricted stock units 38,662,368 285,361 Warrants 32,268,677 10,282,292 Series Seed redeemable convertible preferred stock — 18,193,515 Series A redeemable convertible preferred stock — 46,267,422 Total 79,535,681 86,928,169 Comprehensive Loss There were no differences between net loss and comprehensive loss presented in the consolidated condensed statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021. Recent Accounting Pronouncements Recently Issued Accounting Pronouncements Not Yet Adopted In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . The ASU simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt—Debt with Conversion and Other Options , for convertible instruments. The ASU updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging , or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. Further, the ASU made amendments to the EPS guidance in Topic 260 for convertible instruments, the most significant impact of which is requiring the use of the if-converted method for diluted EPS calculation, and no longer allowing the net share settlement method. The ASU also made revisions to Topic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. The amendments to Topic 815-40 change the scope of contracts that are recognized as assets or liabilities. The ASU is effective for public business entities, excluding smaller reporting companies, for interim and annual periods beginning after December 15, 2021, with early adoption permitted. For all other entities, the amendments are effective for interim and annual periods beginning after December 15, 2023. Adoption of the ASU can either be on a modified retrospective or full retrospective basis. The Company is currently evaluating the impact the adoption of this standard will have on its financial statements and related disclosures. No other recently issued accounting pronouncements had or are expected to have a material impact on the Company’s financial statements.

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
Property and Equipment, Net	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	Property and Equipment, Net Property and equipment, net, consisted of the following (in millions): March 31, December 31, Furniture, fixtures, and equipment $ 3.0 $ 2.8 Computer hardware 2.8 2.5 Computer software 0.5 0.5 Website design 0.5 0.5 Leasehold improvements 1.0 1.0 Construction in progress 0.1 — Total property and equipment 7.9 7.3 Less: Accumulated depreciation (2.0) (1.4) Total property and equipment, net $ 5.9 $ 5.9 The following table presents depreciation expense included in each respective expense category in the consolidated condensed statements of operations and comprehensive loss (in millions): Three Months Ended March 31, 2022 2021 Research and development $ 0.4 $ 0.1 General and administrative 0.2 0.1 Total depreciation expense $ 0.6 $ 0.2

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	3 Months Ended
Accrued Expenses and Other Current Liabilities	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Accrued Expenses and Other Current Liabilities	Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in millions): March 31, December 31, Accrued professional fees $ 13.7 $ 6.9 Accrued employee costs 4.0 2.6 Accrued parts and materials 0.1 0.9 Taxes payable 0.6 0.6 Accrued capital expenditures 0.1 0.4 Accrued marketing fees 0.1 0.3 Other current liabilities 0.8 0.6 Total $ 19.4 $ 12.3

Notes Payable

Notes Payable	3 Months Ended
Notes Payable	Mar. 31, 2022
Debt Disclosure [Abstract]
Notes Payable	Notes Payable Long-term notes payable consisted of the following (in millions): March 31, December 31, Silicon Valley Bank (“SVB”) Term Loans $ 17.5 $ 20.0 Term Loans unamortized discount and loan issuance costs (1.0) (1.2) Total debt, net of discount and loan issuance costs 16.5 18.8 Less current portion, net of discount and loan issuance costs (9.5) (9.5) Total long-term notes payable, net of discount and loan issuance costs $ 7.0 $ 9.3 SVB Loan On July 9, 2021, the Company, as the borrower, entered into a Loan and Security Agreement with SVB and SVB Innovation Credit Fund VIII, L.P. (“SVB Innovation”) as the lenders, and SVB as the collateral agent. The total principal amount of the loans is $20 million (the “Term Loans”), and all obligations due under the Term Loans are collateralized by all of the Company’s right, title, and interest in and to its specified personal property in favor of the collateral agent. The Term Loans include events of default and covenant provisions, whereby accelerated repayment may result if the Company were to default. On January 1, 2022, the Company began repaying the Term Loans, which are payable in 24 equal monthly installments, including principal and interest. The interest rate on the loans is a floating rate per annum equal to the greater of (i) 8.5% and (ii) the Prime Rate plus the Prime Rate Margin (each as defined in the Loan and Security Agreement), which increases by 2% per annum upon the occurrence of an event of default. For the three months ended March 31, 2022, the Company recognized interest expense of $0.4 million. Additionally, in conjunction with the issuance of the Term Loans, the Company issued 366,140 warrants to SVB and 366,140 warrants to SVB Innovation, totaling 732,280 warrants. The Company issued the warrants to the lenders as consideration for entering into the Term Loans, representing a loan issuance fee. Each warrant provides SVB and SVB Innovation with the right to purchase one share of the Company’s Class A common stock. The Company recorded the warrants as liabilities at their fair value and adjust the warrants to fair value at each reporting period. This liability is subject to remeasurement at each balance sheet date until exercised, and any change in fair value is recognized as a gain or loss in the Company’s consolidated condensed statements of operations and comprehensive loss. The initial offsetting entry to the warrant liability was a debt discount recorded to reflect the loan issuance fee. See Note 12 - Liability Classified Warrants for further details. Upon the closing of the Business Combination, the SVB warrants became public warrants. The subsequent measurement of the SVB warrants as of March 31, 2022 is classified as Level 1 due to the use of an observable market quote in an active market under the ticker “ACHR WS.” The quoted price of the public warrants was $0.91 as of March 31, 2022. During the three months ended March 31, 2022, the Company recognized interest expense of $0.2 million related to the amortization of the discount and issuance costs. The unamortized balance of the discount and issuance costs was $1.0 million as of March 31, 2022. The future scheduled principal maturities of notes payable as of March 31, 2022 are as follows (in millions): Remaining 2022 $ 7.5 2023 10.0 $ 17.5

Commitment and Contingencies

Commitment and Contingencies	3 Months Ended
Commitment and Contingencies	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Operating Leases The Company leases office, lab, hangar, and storage facilities under various operating lease agreements with lease periods expiring between 2022 and 2026 and generally containing periodic rent increases and various renewal and termination options. On January 14, 2022, the Company entered into a sublease agreement with Forescout Technologies, Inc. The sublease is for approximately 96,000 rentable square feet of building space in the building located at 190 West Tasman Drive, San Jose, California. The Company intends that the premises will become its corporate headquarters. The term of the sublease commenced on February 26, 2022 and will expire on October 31, 2026, with no right to extend. The Company is also responsible for certain other costs under the sublease, such as certain build-out expenses, operating expenses, taxes, assessments, insurance, and utilities. On March 9, 2022, the Company entered into a lease agreement with SIR Properties Trust. The lease is for approximately 68,000 rentable square feet of building space in the building located at 77 Rio Robles, San Jose, California. The Company intends that the premises will be used for lab space and a low rate initial production facility. The term of the lease commences 210 days after the landlord delivers possession of the premises to the Company, subject to certain demolition work being completed, and will expire 90 months thereafter, with an option for the Company to extend the term for one additional five-year period. Base rent payments due under the lease are expected to be approximately $15.0 million in the aggregate over the term of the lease. The Company is also responsible for certain other costs under the lease, such as certain build-out expenses, operating expenses, taxes, assessments, insurance, and utilities. However, the lease requires that the landlord shall provide the Company with an allowance that may be applied against certain of the Company’s build-out and moving expenses. As of March 31, 2022, the lease has not commenced. The Company’s lease costs were as follows (in millions): Three Months Ended March 31, 2022 2021 Operating lease cost $ 1.1 $ 0.3 The Company’s weighted-average remaining lease term and discount rate were as follows: Three Months Ended March 31, 2022 2021 Weighted-average remaining lease term (in months) 43 27 Weighted-average discount rate 11.36 % 11.39 % The minimum aggregate future obligations under the Company’s non-cancelable operating leases as of March 31, 2022 were as follows (in millions): Remaining 2022 $ 3.4 2023 3.8 2024 2.8 2025 2.9 2026 2.5 Total future lease payments 15.4 Less: imputed interest (3.0) Present value of future lease payments $ 12.4 Supplemental cash flow information and non-cash activities related to right-of-use assets and lease liabilities were as follows (in millions): Three Months Ended March 31, 2022 2021 Operating cash outflows from operating leases $ 0.9 $ 0.3 Operating lease assets obtained in exchange for new lease liabilities 9.1 0.8 Letters of Credit On February 23, 2022, in conjunction with the sublease the Company entered into for its new corporate headquarters, the Company entered into a standby letter of credit in the amount of $1.5 million in favor of the lessor, to satisfy the security deposit or other obligations of the leased property. The standby letter of credit will be automatically reduced and renewed annually through February 1, 2026. In addition, on March 31, 2022, in conjunction with the lease the Company entered into for its new lab space and low rate initial production facility, the Company entered into a standby letter of credit in the amount of $1.2 million in favor of the lessor, to satisfy the security deposit of the leased property. The standby letter of credit automatically renews annually through September 28, 2030. As of March 31, 2022, the Company had standby letters of credit in the aggregate outstanding amount of $2.9 million, secured with restricted cash, to support three of the Company’s leased properties. Litigation During the ordinary course of the business, the Company may be subject to legal proceedings, various claims, and litigation. Such proceedings can be costly, time consuming, and unpredictable, and therefore, no assurance can be given that the final outcome of such proceedings will not materially impact financial condition or results of operations. Wisk Litigation and Government Investigation On April 6, 2021, Wisk Aero LLC (“Wisk”) brought a lawsuit against the Company in the United States District Court for the Northern District of California (the “District Court”) alleging misappropriation of trade secrets and patent infringement. The Company has filed certain counterclaims for defamation, tortious interference and unfair competition. On May 19, 2021, Wisk filed a motion for preliminary injunction and expedited discovery. On June 23, 2021, the Company filed an opposition to the motion for preliminary injunction. On July 22, 2021, the District Court denied Wisk’s motion for preliminary injunction. On August 20, 2021, Wisk filed a notice of appeal of the District Court’s denial of the motion for preliminary injunction. On September 30, 2021, Wisk withdrew its notice of appeal of the District Court’s denial of the motion for preliminary injunction. On January 19, 2022, the Company filed a motion for judgment on the pleadings to dismiss two of Wisk’s asserted patents as invalid, which the District Court granted on April 19, 2022. The District Court separately ordered Wisk to narrow its trade secret case to 10 of the 52 alleged trade secrets and its patent case to eight claims across all patents by September 1, 2022. A trial on Wisk’s claims and the Company’s counterclaims has been scheduled to begin on April 17, 2023. On April 6, 2022, the Company brought a lawsuit against The Boeing Company (“Boeing”) in the Superior Court of California, County of Santa Clara (the “Superior Court”), asserting substantially the same claims set forth in the Company’s counterclaims against Wisk. On April 11, 2022, the Superior Court issued an order staying discovery and the responsive pleading deadline until after the case management conference set for August 2022. The Company continues to strongly believe Wisk’s lawsuit is without merit. The Company will continue to vigorously defend itself against Wisk’s claims and pursue the Company’s counterclaims against Wisk and its claims against Boeing. Because these proceedings are still in the early stages, the Company cannot predict their outcome or impact on the Company and its business. As such, and in consideration of the above, the Company has concluded that a potential loss amount or a potential range of loss is not probable or reasonably estimable under ASC 450, Contingencies , and therefore has not accrued any amounts related to the award of damages or settlement of this matter with Wisk. Therefore, a negative result in these proceedings could have a material adverse effect on the Company’s financial position, liquidity, operations, and cash flows. Prior to Wisk bringing the lawsuit against the Company, on March 30, 2021, one of the Company’s employees, who is a former employee of Wisk, had a search warrant executed at his home in connection with a federal investigation. The Company placed this former Wisk employee on paid administrative leave in connection with this government investigation. In relation to the same investigation, the Company and three of its employees, who are also former Wisk employees, received grand jury subpoenas from the United States Attorney’s Office for the Northern District of California. On January 28, 2022, the U.S. Attorney’s Office informed the Company that, based on its review, it decided not to bring charges against this employee and does not intend to continue its investigation.

Preferred and Common Stock

Preferred and Common Stock	3 Months Ended
Preferred and Common Stock	Mar. 31, 2022
Equity [Abstract]
Preferred and Common Stock	Preferred and Common Stock Preferred Stock As of March 31, 2022, no shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock. Class A and Class B Common Stock Except for voting rights and conversion rights, or as otherwise required by applicable law, the shares of the Company’s Class A common stock and Class B common stock have the same powers, preferences, and rights and rank equally, share ratable and are identical in all respects as to all matters. The rights, privileges, and preferences are as follows: Voting Holders of the Company’s Class A common stock are entitled to one vote per share on all matters to be voted upon by the stockholders, and holders of Class B common stock are entitled to ten votes per share on all matters to be voted upon by the stockholders. The holders of Class A common stock and Class B common stock will generally vote together as a single class on all matters submitted to a vote of the stockholders, unless otherwise required by Delaware law or the Company’s amended and restated certificate of incorporation. Dividends Holders of Class A common stock and Class B common stock are entitled to receive such dividends, if any, as may be declared from time to time by the Company’s board of directors in its discretion out of funds legally available therefor. No dividends on common stock have been declared by the Company’s board of directors through March 31, 2022, and the Company does not expect to pay dividends in the foreseeable future. Preemptive Rights Stockholders have no preemptive or other subscription rights and there are no sinking fund or redemption provisions applicable to Class A common stock and Class B common stock. Conversion Each share of Class B common stock is convertible at any time at the option of the holder into one share of Class A common stock. In addition, each share of Class B common stock will automatically convert into one share of Class A common stock upon transfer to a non-authorized holder. In addition, Class B common stock is subject to “sunset” provisions, under which all shares of Class B common stock will automatically convert into an equal number of shares of Class A common stock upon the earliest to occur of (i) the ten-year anniversary of the closing of the Business Combination, (ii) the date specified by the holders of two-thirds of the then outstanding Class B common stock, voting as a separate class, and (iii) when the number of Class B common stock represents less than 10% of the aggregate number of Class A common stock and Class B common stock then outstanding. In addition, each share of Class B common stock will automatically convert into an equal number of Class A common stock upon the earliest to occur of (a) in the case of a founder of the Company, the date that is nine months following the death or incapacity of such founder, and, in the case of any other holder, the date of the death or incapacity of such holder, (b) in the case of a founder of the Company, the date that is 12 months following the date that such founder ceases to provide services to the Company and its subsidiaries as an executive officer, employee or director of the Company, and, in the case of any other holder, immediately at the occurrence of any such event, and (c) in the case of a founder of the Company or any other holder, at least 80% (subject to customary capitalization adjustments) of the Class B common stock held by such founder or holder (on a fully as converted/as exercised basis) as of immediately following the closing of the Business Combination having been transferred (subject to exceptions for certain permitted transfers). During the three months ended March 31, 2022, 1,757,980 shares of Class B common stock were converted into Class A common stock. Liquidation In the event of the Company’s voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up, subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company’s common stock will be entitled to receive an equal amount per share of all of the Company’s assets of whatever kind available for distribution to stockholders, after the rights of the holders of any preferred stock have been satisfied.

Stock-Based Compensation_

Stock-Based Compensation	3 Months Ended
Stock-Based Compensation	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation 2021 Plan In August 2021, the Company adopted the 2021 Equity Incentive Plan (the “2021 Plan”), which was approved by the stockholders of the Company in September 2021 and became effective immediately upon the closing of the Business Combination. The 2021 Plan provides for the grant of incentive and non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, performance awards, and other awards to employees, directors, and non-employees. Initially, the aggregate number of shares of Class A common stock that may be issued under the plan will not exceed 7,453,588 shares. In addition, the number of shares of Class A common stock reserved for issuance under the 2021 Plan will automatically increase on January 1st of each year, starting on January 1, 2022 and ending on December 31, 2030, in an amount equal to the lesser of (1) 2.0% of the total number of shares of Class A common stock outstanding on December 31 of the preceding year, or (2) a lesser number of Class A common stock determined by the board of directors prior to the date of the increase. In accordance therewith, the number of shares of Class A common stock reserved for issuance under the 2021 Plan increased by 3,255,791 shares on January 1, 2022. In connection with the adoption of the 2021 Plan, the Company ceased issuing awards under its 2019 Equity Incentive Plan (the “2019 Plan”). Following the closing of the Business Combination, the Company assumed the outstanding stock options under the 2019 Plan and converted such stock options into options to purchase the Company’s common stock. Such stock options will continue to be governed by the terms of the 2019 Plan and the stock option agreements thereunder, until such outstanding options are exercised or until they terminate or expire. Employee Stock Purchase Plan In August 2021, the Company adopted the 2021 Employee Stock Purchase Plan (the “ESPP”), which became effective immediately upon the closing of the Business Combination. The ESPP permits eligible employees to purchase shares of Class A common stock at a price equal to 85% of the lower of the fair market value of Class A common stock on the first day of an offering or on the date of purchase. The maximum number of shares of Class A common stock that may be issued under the ESPP will not exceed 4,969,059 shares. Additionally, the number of shares of Class A common stock reserved for issuance under the ESPP will automatically increase on January 1st of each year, beginning on January 1, 2022 and continuing through and including January 1, 2031, by the lesser of (i) 1.0% of the total number of shares of Class A common stock outstanding on December 31st of the preceding calendar year; (ii) 9,938,118 shares of Class A common stock; or (iii) such lesser number of shares of the Company as determined by the board of directors. In accordance therewith, the number of shares of Class A common stock reserved for issuance under the ESPP increased by 1,627,895 on January 1, 2022. As of March 31, 2022, there have been no purchases under the ESPP, and therefore, no shares have been issued. Quarterly Equity Awards Subject to the achievement of certain performance goals established by the Company from time to time, the Company’s employees are eligible to receive an annual incentive bonus that will entitle them to a quarterly grant of a number of restricted stock units (“RSUs”) determined by dividing 25% of the annual bonus target amount by the closing price of the Company’s Class A common stock on the date of grant. The RSUs will be fully vested on the date of grant. Furthermore, all the quarterly equity awards are contingent and issued only upon approval by the Company’s board of directors. During the three months ended March 31, 2022, the Company recognized stock-based compensation expense of $1.8 million related to these quarterly equity awards, which are expected to be granted in the subsequent fiscal quarter. Stock Options A summary of the Company’s stock option activity is as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (In millions) Outstanding as of January 1, 2022 9,444,221 $ 0.12 8.66 $ 55.9 Exercised (753,261) 0.12 2.7 Expired/forfeited (86,324) 0.13 Outstanding as of March 31, 2022 8,604,636 0.12 8.41 40.4 Exercisable as of March 31, 2022 952,603 0.12 8.30 4.5 Vested and expected to vest as of March 31, 2022 8,604,636 0.12 8.41 40.4 The Company recognized stock-based compensation expense of $1.0 million and $0.9 million for stock options for the three months ended March 31, 2022 and 2021, respectively. As of March 31, 2022, the total remaining stock-based compensation expense for unvested stock options was $12.7 million, which is expected to be recognized over a weighted-average period of 1.3 years. Restricted Stock Units A summary of the Company’s RSU activity is as follows: Number of Shares Weighted Average Grant Price Outstanding as of January 1, 2022 36,249,396 $ 6.53 Granted 1,462,209 3.06 Vested (300,014) 5.07 Forfeited (624,223) 7.19 Outstanding as of March 31, 2022 36,787,368 6.39 In February 2022, the Company granted 1,462,209 RSUs under the 2021 Plan. The RSUs generally vest over a three Immediately prior to closing of the Business Combination, each of the Company’s founders was granted 20,009,224 RSUs under the 2019 Plan pursuant to the terms and conditions of the Business Combination Agreement (the “Founder Grants”). Considering each of the founder’s existing equity ownership and assuming the Founder Grants fully vest, it would result in each of the founders owning approximately 18% of all outstanding shares of the Total Outstanding Capitalization of the Company (as defined in the Business Combination Agreement). One-quarter of each Founder Grant vests upon the achievement of the earlier to occur of (i) a price-based milestone or (ii) a performance-based milestone, with a different set of such price and performance-based milestones applying to each quarter of each Founder Grant and so long as the achievement occurs within seven years following the closing of the Business Combination. The Company accounts for the Founder Grants as four separate tranches, with each tranche consisting of two award grants, a performance award grant and market award grant. Each tranche vests when either the market condition or performance condition is satisfied (only one condition is satisfied). The Company determined the fair value of the performance award by utilizing the trading price on the Closing Date. When the applicable performance milestone is deemed probable of being achieved, the Company will recognize compensation expense for the portion earned to date over the requisite period. For the market award, the Company determined both the fair value and derived service period using a Monte Carlo simulation model on the Closing Date. The Company will recognize compensation expense for the market award on a straight-line basis over the derived service period. If the applicable performance condition is not probable of being achieved, compensation cost for the value of the award incorporating the market condition is recognized, so long as the requisite service is provided. If the performance milestone becomes probable of being achieved, the full fair value of the award will be recognized, and any remaining expense for the market award will be canceled. One-quarter of each Founder Grant, totaling 5,002,306 shares each of Class B common stock, vested immediately prior to the Closing Date pursuant to the terms and conditions of the Business Combination Agreement. During the three months ended March 31, 2022, the Company recorded $16.0 million of expense for the amortized portion of the market award for the remaining three tranches in general and administrative expenses in the consolidated condensed statements of operations and comprehensive loss. For the three months ended March 31, 2022 and 2021, the Company recorded $5.7 million and less than $0.1 million of stock-based compensation expense, respectively, related to RSU awards. As of March 31, 2022, the total remaining stock-based compensation expense for unvested RSUs was $300.1 million, which is expected to be recognized over a weighted-average period of 2.3 years. The Company records stock-based compensation expense for stock-based compensation awards based on the fair value on the date of grant. The stock-based compensation expense is recognized ratably over the course of the requisite service period. The Company has elected to account for forfeitures as they occur and will record stock-based compensation expense assuming all stockholders will complete the requisite service period. If an employee forfeits an award because they fail to complete the requisite service period, the Company will reverse stock-based compensation expense previously recognized in the period the award is forfeited. The following table presents stock-based compensation expense included in each respective expense category in the statements of operations and comprehensive loss (in millions): Three Months Ended March 31, 2022 2021 Research and development $ 5.4 $ 0.7 General and administrative 19.1 0.2 Total stock-based compensation expense $ 24.5 $ 0.9 Warrants A summary of the Company’s warrant activity is as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (In millions) Outstanding as of January 1, 2022 8,644,932 $ 0.01 8.87 $ 52.1 Issued — — Exercised — — — Outstanding as of March 31, 2022 8,644,932 0.01 8.87 52.1 Vested and exercisable as of March 31, 2022 1,775,202 $ 0.01 3.82 $ 8.5 United Airlines On January 29, 2021, the Company entered into a Purchase Agreement (the “Purchase Agreement”), Collaboration Agreement (the “United Collaboration Agreement”), and Warrant Agreement with United Airlines, Inc. (“United”). Under the terms of the Purchase Agreement, United has a conditional purchase order for up to 200 of the Company’s aircraft, with an option to purchase an additional 100 aircraft. Those purchases are conditioned upon the Company meeting certain conditions that include, but are not limited to, the certification of the Company’s aircraft by the FAA and further negotiation and reaching of mutual agreement on certain material terms related to the purchases. The Company issued 14,741,764 warrants to United to purchase shares of the Company’s Class A common stock. Each warrant provides United with the right to purchase one share of the Company’s Class A common stock at an exercise price of $0.01 per share. The warrants vest in four equal installments in accordance with the following milestones: the execution of the Purchase Agreement and the United Collaboration Agreement, the completion of the Business Combination, the certification of the aircraft by the FAA, and the initial sale of aircraft to United. The Company accounts for the Purchase Agreement and the United Collaboration Agreement under ASC 606, Revenue from Contracts with Customers . The Company identified the sale of each aircraft ordered by United as a separate performance obligation in the contract. As the performance obligations have not been satisfied, the Company has not recognized any revenue as of March 31, 2022. With respect to the four warrant vesting milestones outlined above, the Company accounts for them as consideration payable to a customer under ASC 606 related to the future purchase of aircraft by United. Pursuant to ASC 718, Compensation — Stock Compensation, the Company measured the grant date fair value of the warrants to be recognized upon the achievement of each of the four milestones and the vesting of the related warrants. The Company determined that the warrants will be classified as equity awards based on the criteria of ASC 480, Distinguishing Liabilities from Equity and ASC 718. For the first milestone, issuance of the warrants in conjunction with the execution of the Purchase Agreement and the United Collaboration Agreement, the Company recorded the grant date fair value of the respective warrant tranche at the vesting date upon satisfaction of the milestone, and the related costs were recorded in other warrant expense due to the absence of historical or probable future revenue. For the second milestone, the completion of the Business Combination transaction, the related costs were also recorded in other warrant expense due to the absence of historical or probable future revenue. For the third milestone, the certification of the aircraft by the FAA, the Company will assess whether it is probable that the award will vest at the end of every reporting period. If and when the award is deemed probable of vesting, the Company will begin capitalizing the grant date fair value of the associated warrants as an asset through the vesting date and subsequently amortize the asset as a reduction to revenue as it sells the new aircraft to United. For the fourth milestone, the sale of aircraft to United, the Company will record the cost associated with the vesting of each portion of warrants within this milestone as a reduction of the transaction price as revenue is recognized for each sale of the aircraft. During the three months ended March 31, 2022, no other warrant expense was recognized. During the three months ended March 31, 2021, the Company recorded $78.2 million in other warrant expense in the consolidated condensed statements of operations and comprehensive loss related to the achievement of the first milestone. A total of 8,845,058 warrants vested from achievement of the first two milestones and were exercised during the fiscal year ended December 31, 2021. FCA US LLC On November 6, 2020, the Company entered into a Collaboration Agreement with FCA US LLC (“FCA”) (the “FCA Collaboration Agreement”), in which both parties agreed to work together to complete a series of fixed duration collaboration projects related to the Company’s ongoing efforts to design, develop, and bring up production capabilities for its aircraft. The Company issued a warrant to FCA on November 6, 2020, in which FCA has the right to purchase up to 1,671,202 shares of the Company’s Class A common stock at an exercise price of $0.01 per share (subject to appropriate adjustment in the event of a stock dividend, stock split, combination, or other similar recapitalization). Shares under the warrant vest based on the completion of specific aircraft development milestones identified under the FCA Collaboration Agreement, which are expected to be achieved on a rolling basis through December 2022. As the Company is currently in pre-revenue stage and is not generating any revenue from the FCA Collaboration Agreement, all costs incurred with third parties are recorded based on the nature of the cost incurred. The Company accounts for the warrant in accordance with the provisions of ASC 718. The Company will assess whether it is probable that the award will vest for each of the seven milestones at the end of every reporting period. If and when the award is deemed probable of vesting, the Company will recognize compensation expense for the portion of the grant determined probable of vesting on a straight-line basis over the duration of each milestone. If services had been provided by FCA prior to management determining the milestone is probable of being achieved, a cumulative catch-up adjustment will be recorded for services performed in prior periods. Costs incurred under the FCA Collaboration Agreement and warrant are associated with the design, development, and bring up of production for the Company’s aircraft. During the three months ended March 31, 2022 and 2021, the Company recorded less than $0.1 million of R&D expense in each period in the consolidated condensed statements of operations and comprehensive loss related to the completion of certain milestones. As of March 31, 2022, a total of five milestones have been completed, amounting to 1,236,690 shares that have vested. FCA Italy S.p.A. On July 19, 2021, the Company entered into a Manufacturing Consulting Agreement with an affiliate of FCA, FCA Italy S.p.A. (“FCA Italy”) (the “Manufacturing Consulting Agreement”), in which both parties agreed to work together to complete a series of fixed duration projects to develop manufacturing and production processes in connection with the Company’s ongoing efforts to bring up production capabilities for its aircraft. In conjunction with the Manufacturing Consulting Agreement, the Company issued a warrant to FCA Italy, in which FCA Italy has the right to purchase up to 1,077,024 shares of the Company’s Class A common stock at an exercise price of $0.01 per share. The shares underlying the warrant vest in two equal installments in accordance with two time-based milestones. The Company accounts for the warrant in accordance with ASC 718. The Company recognized compensation cost for half of the shares that were fully vested upon execution of the Manufacturing Consulting Agreement. The Company will recognize compensation cost for the remaining half of the warrant as the related services are received from FCA Italy on a straight-line basis over the service period of 12 months. During the three months ended March 31, 2022, the Company recorded $1.2 million of R&D expense in the consolidated condensed statements of operations and comprehensive loss related to services received during the period for the second milestone.

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company recognized zero and less than $0.1 million of income tax expense for the three months ended March 31, 2022 and 2021, respectively, resulting in an effective tax rate of 0%. The effective tax rate is different from the federal statutory tax rate primarily due to a full valuation allowance against deferred tax assets. In assessing the realizability of deferred tax assets, management considers whether it is more-likely-than-not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which those temporary differences become deductible. Based upon the analysis of federal and state deferred tax balances, future tax projections, and the Company’s lack of taxable income in the carryback period, the Company recorded a full valuation allowance against the federal and state deferred tax assets as of March 31, 2022 and 2021.

401(k) Savings Plan_

401(k) Savings Plan	3 Months Ended
401(k) Savings Plan	Mar. 31, 2022
Retirement Benefits [Abstract]
401(k) Savings Plan	401(k) Savings PlanThe Company maintains a 401(k) savings plan for the benefit of its employees. The Company makes matching contributions equal to 50% of each employee contribution, subject to the maximum amount established by the Internal Revenue Service. All current employees are eligible to participate in the 401(k) savings plan. The Company’s matching contributions were approximately $0.5 million and $0.1 million for the three months ended March 31, 2022 and 2021, respectively.

Liability Classified Warrants

Liability Classified Warrants	3 Months Ended
Liability Classified Warrants	Mar. 31, 2022
Warrants and Rights Note Disclosure [Abstract]
Liability Classified Warrants	Liability Classified Warrants As of March 31, 2022, there were 17,398,947 public w arrants outstanding. Public warrants may only be exercised for a whole number of shares. No fractional shares are issued upon exercise of the public warrants. The public warrants became exercisable on October 30, 2021, 12 months after the closing of the initial public offering of Atlas. The public warrants will expire five years from the consummation of the Business Combination or earlier upon redemption or liquidation. Once the public warrants become exercisable, the Company may redeem the public warrants for redemption: • in whole and not in part; • at a price of $0.01 per public warrant; • upon not less than 30 days’ prior written notice of redemption to each warrant holder; and • if, and only if, the closing price of the Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period commencing after the warrants become exercisable and ending three business days before the Company sends the notice of redemption to the warrant holders. If and when the warrants become redeemable by the Company, the Company may exercise its redemption right even if the Company is unable to register or qualify the underlying securities for sale under all applicable state securities laws. Each public warrant entitles the registered holder to purchase one share of Class A common stock at a price of $11.50 per share. The exercise price and number of Class A common stock issuable upon exercise of the public warrants may be adjusted in certain circumstances including in the event of a share dividend, extraordinary dividend or recapitalization, reorganization, merger or consolidation. The public warrants will not be adjusted for issuances of Class A common stock at a price below its exercise price. Additionally, in no event will the Company be required to net cash settle the public warrants. As of March 31, 2022, there were 8,000,000 private placement warrants outstanding. The private placement warrants are identical to the public warrants underlying the shares sold in the initial public offering of Atlas, except that the private placement warrants and the shares of Class A common stock issuable upon the exercise of the private placement warrants became transferable, assignable, and salable on October 16, 2021, 30 days after the completion of the Business Combination, subject to certain limited exceptions. Additionally, the private placement warrants will be exercisable on a cashless basis and will be non-redeemable so long as they are held by the initial purchasers or their permitted transferees. If the private placement

Subsequent Events

Subsequent Events	3 Months Ended
Subsequent Events	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On April 18, 2022, the Company announced a leadership transition to a sole CEO, which it believes will help simplify its operating structure, and appointed Adam Goldstein to that role. Brett Adcock’s service as the Company’s Co-CEO ended effective April 13, 2022 (the “Separation Date”). Mr. Adcock and the Company have entered into a separation agreement (the “Separation Agreement”), dated April 28, 2022, pursuant to which Mr. Adcock agreed to a customary general release and waiver of claims, a covenant not to sue the Company, and a twelve month lock-up period related to the transfer of any capital stock (or securities convertible into capital stock) of the Company, subject to a limited exception to (i) sell a limited portion of his holdings in each of the third and fourth quarters of 2022 and the first quarter of 2023 and (ii) transfer shares in connection with the payment of taxes associated with the settlement of shares underlying the Founder Grant (as defined in Note 9 - Stock-Based Compensation). The Separation Agreement entitles Mr. Adcock to receive certain severance benefits after the Separation Date, including but not limited to: (i) salary continuation payments based on his current salary of $600,000 for a period of twenty-four months, less standard payroll deductions and tax withholdings; (ii) an additional cash bonus severance payment equal to $600,000, which equals two times the amount of Mr. Adcock’s target annual bonus for 2022; (iii) a cash severance payment with respect to COBRA premiums equal to $64,602.48; (iv) twenty-four months of accelerated vesting of Mr. Adcock’s unvested shares subject to time-based equity awards (excluding the Founder Grant); (v) eligibility for continued vesting upon the achievement of certain milestones of the Founder Grant that will remain outstanding for fifteen months following the Separation Date; and (vi) an additional payment equal to $1,500,000. On May 9, 2022, the Board of Directors of the Company received a letter from Mr. Adcock resigning as a director of the Company, effective immediately.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated condensed financial statements have been prepared pursuant to the rules and regulations of the SEC for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America (“U.S. GAAP”) for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of financial position, results of operations, and cash flows for the interim periods presented have been reflected herein. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year. The unaudited consolidated condensed financial statements should be read in conjunction with the Company’s audited consolidated financial statements as of and for the fiscal year ended December 31, 2021 set forth in the Company’s Annual Report on Form 10-K. The December 31, 2021 consolidated condensed balance sheet was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.
Cash, Cash Equivalents, and Restricted Cash	Cash, Cash Equivalents, and Restricted CashCash consists of cash on deposit with financial institutions. Cash equivalents consist of short-term, highly liquid financial instruments that are readily convertible to cash and have maturities of three months or less from the date of purchase. The Company’s c
Fair Value Measurements	Fair Value Measurements The Company applies the provisions of Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which defines a single authoritative definition of fair value, sets out a framework for measuring fair value and expands on required disclosures about fair value measurements. The provisions of ASC 820 relate to financial assets and liabilities as well as other assets and liabilities carried at fair value on a recurring and nonrecurring basis. The standard clarifies that fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the standard establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date. Level 2 Other than quoted prices included in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability. Level 3 Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date. Private Placement Warrants The Company utilizes a Monte Carlo simulation model for the private placement warrants at each reporting period, with changes in fair value recognized in the statement of operations and comprehensive loss. The estimated fair value of the private placement warrant liability is determined using Level 3 inputs. Inherent in a binomial options pricing model and Monte Carlo simulation model are assumptions related to expected share-price volatility, expected life, risk-free interest rate, and dividend yield. Financial Instruments Not Recorded at Fair Value on a Recurring Basis Certain financial instruments, including debt, are not measured at fair value on a recurring basis in the balance sheets. The fair value of debt as of March 31, 2022 approximates its carrying value. Assets and Liabilities Recorded at Fair Value on a Non-Recurring Basis Certain assets and liabilities are subject to measurement at fair value on a non-recurring basis if there are indicators of impairment or if they are deemed to be impaired as a result of an impairment review.
Intangible Assets, Net	Intangible Assets, Net Intangible assets consist solely of domain names and are recorded at cost, net of accumulated amortization, and if applicable, impairment charges. Amortization of domain names is provided over a 15-year estimated useful life on a straight-line basis or based on the pattern in which economic benefits are consumed, if reliably determinable. The Company reviews intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company has analyzed a variety of factors in light of the known impact to date of the COVID-19 pandemic on the Company’s business to determine if any circumstance could trigger an impairment loss, and, at this time and based on the information presently known, do not believe that it is more likely than not that an impairment loss has been incurred.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares outstanding. For all periods presented, the calculation of basic net loss per share excludes shares issued upon the early exercise of stock options where the vesting conditions have not been satisfied. Because the Company reported net losses for all periods presented, diluted loss per share is the same as basic loss per share. Contingently issuable shares, including equity awards with performance conditions, are considered outstanding common shares and included in basic net loss per share as of the date that all necessary conditions to earn the awards have been satisfied. Prior to the end of the contingency period, the number of contingently issuable shares included in diluted net loss per share is based on the number of shares, if any, that would be issuable under the terms of the arrangement at the end of the reporting period. Because the Company reported net losses for all periods presented, all potentially dilutive common stock equivalents are antidilutive and have been excluded from the calculation of net loss per share. The diluted net loss per common share was the same for Class A and Class B common shares because they are entitled to the same liquidation and dividend rights.
Comprehensive Loss	Comprehensive Loss There were no differences between net loss and comprehensive loss presented in the consolidated condensed statements of operations and comprehensive loss for the three months ended March 31, 2022 and 2021.
Recent Accounting Pronouncements and Recently Issued Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements Recently Issued Accounting Pronouncements Not Yet Adopted In August 2020, the Financial Accounting Standards Board (“FASB”) issued ASU 2020-06, Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity . The ASU simplifies the accounting for convertible instruments by removing certain separation models in ASC 470-20, Debt—Debt with Conversion and Other Options , for convertible instruments. The ASU updates the guidance on certain embedded conversion features that are not required to be accounted for as derivatives under Topic 815, Derivatives and Hedging , or that do not result in substantial premiums accounted for as paid-in capital, such that those features are no longer required to be separated from the host contract. The convertible debt instruments will be accounted for as a single liability measured at amortized cost. Further, the ASU made amendments to the EPS guidance in Topic 260 for convertible instruments, the most significant impact of which is requiring the use of the if-converted method for diluted EPS calculation, and no longer allowing the net share settlement method. The ASU also made revisions to Topic 815-40, which provides guidance on how an entity must determine whether a contract qualifies for a scope exception from derivative accounting. The amendments to Topic 815-40 change the scope of contracts that are recognized as assets or liabilities. The ASU is effective for public business entities, excluding smaller reporting companies, for interim and annual periods beginning after December 15, 2021, with early adoption permitted. For all other entities, the amendments are effective for interim and annual periods beginning after December 15, 2023. Adoption of the ASU can either be on a modified retrospective or full retrospective basis. The Company is currently evaluating the impact the adoption of this standard will have on its financial statements and related disclosures. No other recently issued accounting pronouncements had or are expected to have a material impact on the Company’s financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	3 Months Ended
Summary of Significant Accounting Policies (Tables)	Mar. 31, 2022
Accounting Policies [Abstract]
Schedule of Cash, Cash Equivalents, and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the balance sheets that sum to amounts reported on the statements of cash flows: March 31, December 31, Cash and cash equivalents $ 704.2 $ 746.6 Restricted cash 2.9 0.3 Total cash, cash equivalents, and restricted cash $ 707.1 $ 746.9
Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2022 and December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Description Level March 31, December 31, (In millions) Assets: Money Market Funds 1 $ 0.3 $ 0.3 Liabilities: Warrant Liability – Public Warrants 1 $ 15.9 $ 20.2 Warrant Liability – Private Placement Warrants 3 $ 7.9 $ 10.1
Fair Value Measurement Inputs and Valuation Techniques	The key inputs into the Monte Carlo simulation model for the private placement warrants are as follows: Input March 31, December 31, Stock price $ 4.81 $ 6.04 Strike price $ 11.50 $ 11.50 Dividend yield 0.00 % 0.00 % Term (in years) 4.46 4.71 Volatility 51.1 % 45.3 % Risk-free rate 2.43 % 1.22 %
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table presents the change in fair value of the Company’s Level 3 private placement warrants during the three months ended March 31, 2022 (in millions): Balance as of December 31, 2021 $ 10.1 Change in fair value (2.2) Balance as of March 31, 2022 $ 7.9
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following table presents the number of antidilutive shares excluded from the calculation of diluted net loss per share: Three Months Ended March 31, 2022 2021 Options to purchase common stock 8,604,636 11,899,579 Unvested restricted stock units 38,662,368 285,361 Warrants 32,268,677 10,282,292 Series Seed redeemable convertible preferred stock — 18,193,515 Series A redeemable convertible preferred stock — 46,267,422 Total 79,535,681 86,928,169

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
Property and Equipment, Net (Tables)	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment Net	Property and equipment, net, consisted of the following (in millions): March 31, December 31, Furniture, fixtures, and equipment $ 3.0 $ 2.8 Computer hardware 2.8 2.5 Computer software 0.5 0.5 Website design 0.5 0.5 Leasehold improvements 1.0 1.0 Construction in progress 0.1 — Total property and equipment 7.9 7.3 Less: Accumulated depreciation (2.0) (1.4) Total property and equipment, net $ 5.9 $ 5.9 The following table presents depreciation expense included in each respective expense category in the consolidated condensed statements of operations and comprehensive loss (in millions): Three Months Ended March 31, 2022 2021 Research and development $ 0.4 $ 0.1 General and administrative 0.2 0.1 Total depreciation expense $ 0.6 $ 0.2

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
Accrued Expenses and Other Current Liabilities (Tables)	Mar. 31, 2022
Other Liabilities Disclosure [Abstract]
Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following (in millions): March 31, December 31, Accrued professional fees $ 13.7 $ 6.9 Accrued employee costs 4.0 2.6 Accrued parts and materials 0.1 0.9 Taxes payable 0.6 0.6 Accrued capital expenditures 0.1 0.4 Accrued marketing fees 0.1 0.3 Other current liabilities 0.8 0.6 Total $ 19.4 $ 12.3

Notes Payable (Tables)

Notes Payable (Tables)	3 Months Ended
Notes Payable (Tables)	Mar. 31, 2022
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Long-term notes payable consisted of the following (in millions): March 31, December 31, Silicon Valley Bank (“SVB”) Term Loans $ 17.5 $ 20.0 Term Loans unamortized discount and loan issuance costs (1.0) (1.2) Total debt, net of discount and loan issuance costs 16.5 18.8 Less current portion, net of discount and loan issuance costs (9.5) (9.5) Total long-term notes payable, net of discount and loan issuance costs $ 7.0 $ 9.3
Schedule of Maturities of Long-term Debt	The future scheduled principal maturities of notes payable as of March 31, 2022 are as follows (in millions): Remaining 2022 $ 7.5 2023 10.0 $ 17.5

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	3 Months Ended
Commitment and Contingencies (Tables)	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Summary of Lease Costs	The Company’s lease costs were as follows (in millions): Three Months Ended March 31, 2022 2021 Operating lease cost $ 1.1 $ 0.3 The Company’s weighted-average remaining lease term and discount rate were as follows: Three Months Ended March 31, 2022 2021 Weighted-average remaining lease term (in months) 43 27 Weighted-average discount rate 11.36 % 11.39 % Supplemental cash flow information and non-cash activities related to right-of-use assets and lease liabilities were as follows (in millions): Three Months Ended March 31, 2022 2021 Operating cash outflows from operating leases $ 0.9 $ 0.3 Operating lease assets obtained in exchange for new lease liabilities 9.1 0.8
Summary of Operating Lease Maturities	The minimum aggregate future obligations under the Company’s non-cancelable operating leases as of March 31, 2022 were as follows (in millions): Remaining 2022 $ 3.4 2023 3.8 2024 2.8 2025 2.9 2026 2.5 Total future lease payments 15.4 Less: imputed interest (3.0) Present value of future lease payments $ 12.4

Stock-Based Compensation_ (Tabl

Stock-Based Compensation (Tables)	3 Months Ended
Stock-Based Compensation (Tables)	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Share-based Payment Arrangement, Option, Activity	A summary of the Company’s stock option activity is as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (In millions) Outstanding as of January 1, 2022 9,444,221 $ 0.12 8.66 $ 55.9 Exercised (753,261) 0.12 2.7 Expired/forfeited (86,324) 0.13 Outstanding as of March 31, 2022 8,604,636 0.12 8.41 40.4 Exercisable as of March 31, 2022 952,603 0.12 8.30 4.5 Vested and expected to vest as of March 31, 2022 8,604,636 0.12 8.41 40.4
Share-based Payment Arrangement, Restricted Stock Unit, Activity	A summary of the Company’s RSU activity is as follows: Number of Shares Weighted Average Grant Price Outstanding as of January 1, 2022 36,249,396 $ 6.53 Granted 1,462,209 3.06 Vested (300,014) 5.07 Forfeited (624,223) 7.19 Outstanding as of March 31, 2022 36,787,368 6.39
Share-based Payment Arrangement, Expensed and Capitalized, Amount	The following table presents stock-based compensation expense included in each respective expense category in the statements of operations and comprehensive loss (in millions): Three Months Ended March 31, 2022 2021 Research and development $ 5.4 $ 0.7 General and administrative 19.1 0.2 Total stock-based compensation expense $ 24.5 $ 0.9
Share-based Payment Arrangement, Warrant Activity	A summary of the Company’s warrant activity is as follows: Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (Years) Aggregate Intrinsic Value (In millions) Outstanding as of January 1, 2022 8,644,932 $ 0.01 8.87 $ 52.1 Issued — — Exercised — — — Outstanding as of March 31, 2022 8,644,932 0.01 8.87 52.1 Vested and exercisable as of March 31, 2022 1,775,202 $ 0.01 3.82 $ 8.5

Organization and Nature of Bu_2

Organization and Nature of Business (Details)	3 Months Ended
Organization and Nature of Business (Details)	Mar. 31, 2022lineOfBusiness
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of lines of business	2

Liquidity and Going Concern (De

Liquidity and Going Concern (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 432.8	$ 373.6
Reverse recapitalization net proceeds received	801.8
Cash and cash equivalents	$ 704.2	$ 746.6

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Narrative (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022USD ($)$ / shares	Mar. 31, 2021USD ($)	Dec. 31, 2021USD ($)$ / shares
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 704.2		$ 746.6
Change in fair value of warrant liabilities	$ 6.6	$ 0
Finite-lived intangible asset, useful life	15 years
Intangible assets, net	$ 0.4		$ 0.5
Stock price
Cash and Cash Equivalents [Line Items]
Warrant liability, measurement input \| $ / shares	4.81		6.04
Public Warrants \| Stock price
Cash and Cash Equivalents [Line Items]
Warrant liability, measurement input \| $ / shares	0.91
Money Market Funds
Cash and Cash Equivalents [Line Items]
Cash and cash equivalents	$ 0.3		$ 0.3

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Accounting Policies [Abstract]
Cash and cash equivalents	$ 704.2	$ 746.6
Restricted cash	2.9	0.3
Total cash, cash equivalents, and restricted cash	$ 707.1	$ 746.9

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Fair Value Recurring Basis (Details) - Recurring - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Level 1 \| Money Market Funds
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, fair value	$ 0.3	$ 0.3
Level 1 \| Public Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability, fair value disclosure	15.9	20.2
Level 3 \| Private Placement Warrants
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability, fair value disclosure	$ 7.9	$ 10.1

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Measurement Input (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2022$ / shares	Dec. 31, 2021$ / shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants outstanding, term	4 years 5 months 15 days	4 years 8 months 15 days
Stock price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	4.81	6.04
Strike price
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	11.50	11.50
Dividend yield
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	0	0
Volatility
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	0.511	0.453
Risk-free rate
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrant liability, measurement input	0.0243	0.0122

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Private Placement Warrants (Details) - Private Placement Warrants - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 7.9	$ 10.1
Change in fair value	(2.2)
Ending balance	$ 7.9

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Schedule of Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)	79,535,681	86,928,169
Options to purchase common stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)	8,604,636	11,899,579
Unvested restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)	38,662,368	285,361
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)	32,268,677	10,282,292
Series Seed redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)	0	18,193,515
Series A redeemable convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation (in shares)	0	46,267,422

Property and Equipment, Net (De

Property and Equipment, Net (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 7.9	$ 7.3
Less: Accumulated depreciation	(2)	(1.4)
Total property and equipment, net	5.9	5.9
Furniture, fixtures, and equipment
Property, Plant and Equipment [Line Items]
Total property and equipment	3	2.8
Computer hardware
Property, Plant and Equipment [Line Items]
Total property and equipment	2.8	2.5
Computer software
Property, Plant and Equipment [Line Items]
Total property and equipment	0.5	0.5
Website design
Property, Plant and Equipment [Line Items]
Total property and equipment	0.5	0.5
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property and equipment	1	1
Construction in progress
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 0.1	$ 0

Property and Equipment, Net - D

Property and Equipment, Net - Depreciation Expense (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Depreciation
Total depreciation expense	$ 0.6	$ 0.2
Research and development
Depreciation
Total depreciation expense	0.4	0.1
General and administrative
Depreciation
Total depreciation expense	$ 0.2	$ 0.1

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Other Liabilities Disclosure [Abstract]
Accrued professional fees	$ 13.7	$ 6.9
Accrued employee costs	4	2.6
Accrued parts and materials	0.1	0.9
Taxes payable	0.6	0.6
Accrued capital expenditures	0.1	0.4
Accrued marketing fees	0.1	0.3
Other current liabilities	0.8	0.6
Total	$ 19.4	$ 12.3

Notes Payable - Schedule of Lon

Notes Payable - Schedule of Long-term Debt Instruments (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Long-term debt, gross	$ 17.5
Term Loans unamortized discount and loan issuance costs	(1)	$ (1.2)
Total debt, net of discount and loan issuance costs	16.5	18.8
Less current portion, net of discount and loan issuance costs	(9.5)	(9.5)
Total long-term notes payable, net of discount and loan issuance costs	7	9.3
SVB Term Loans \| Secured Debt
Debt Instrument [Line Items]
Long-term debt, gross	17.5	$ 20
Term Loans unamortized discount and loan issuance costs	$ (1)

Notes Payable - Narrative (Deta

Notes Payable - Narrative (Details)	Jul. 09, 2021USD ($)shares	Mar. 31, 2022USD ($)$ / shares	Mar. 31, 2021USD ($)	Jan. 01, 2022installment	Dec. 31, 2021USD ($)$ / shares	Sep. 16, 2021shares
Debt Instrument [Line Items]
Debt discount and issuance cost amortization		$ 200,000	$ 0
Term Loans unamortized discount and loan issuance costs		$ 1,000,000			$ 1,200,000
Stock price
Debt Instrument [Line Items]
Warrant liability, measurement input (in dollars per share) \| $ / shares		4.81			6.04
Warrants For Consideration Of Term Loan
Debt Instrument [Line Items]
Warrants, issued or issuable (in shares) \| shares	732,280
Number of securities called by each warrant or right (in shares) \| shares	1
Public Warrants
Debt Instrument [Line Items]
Number of securities called by each warrant or right (in shares) \| shares						1
Public Warrants \| Stock price
Debt Instrument [Line Items]
Warrant liability, measurement input (in dollars per share) \| $ / shares		0.91
Silicon Valley Bank (“SVB”) \| Warrants For Consideration Of Term Loan
Debt Instrument [Line Items]
Warrants, issued or issuable (in shares) \| shares	366,140
SVB Innovation Credit Fund VIII, L.P. (“SVB Innovation”) \| Warrants For Consideration Of Term Loan
Debt Instrument [Line Items]
Warrants, issued or issuable (in shares) \| shares	366,140
Secured Debt \| SVB Term Loans
Debt Instrument [Line Items]
Debt instrument, face amount	$ 20,000,000
Number of monthly installments \| installment				24
Effective rate					8.50%
Increase in annual interest rate upon event of default		2.00%
Interest expense, debt		$ 400,000
Debt discount and issuance cost amortization		200,000
Term Loans unamortized discount and loan issuance costs		$ 1,000,000

Notes Payable - Maturity Schedu

Notes Payable - Maturity Schedule (Details) $ in Millions	Mar. 31, 2022USD ($)
Debt Disclosure [Abstract]
Remaining 2022	$ 7.5
2023	10
Long-term debt	$ 17.5

Commitment and Contingencies -

Commitment and Contingencies - Narrative (Details) ft² in Thousands	Mar. 09, 2022USD ($)ft²optionToExtend	Mar. 31, 2022USD ($)property	Apr. 19, 2022patentclaim	Feb. 23, 2022USD ($)	Jan. 14, 2022ft²optionToExtend
Debt Instrument [Line Items]
Area of sublease \| ft²	68				96
Number of options to extend the term \| optionToExtend	1				0
Operating lease, liability, to be paid	$ 15,000,000	$ 15,400,000
Commencement term	210 days
Expiration term	90 months
Option to extend, term	5 years
Number of leased properties supported by lines of credit \| property		3
Subsequent Event
Debt Instrument [Line Items]
Number of patents requested for dismissal \| patent			2
Number of original alleged trade secret violations \| claim			52
Standby Letters of Credit \| Line of Credit
Debt Instrument [Line Items]
Line of credit, borrowing capacity		$ 2,900,000		$ 1,500,000
Standby Letters of Credit \| Line of Credit \| Security Deposit
Debt Instrument [Line Items]
Line of credit, borrowing capacity		$ 1,200,000

Commitment and Contingencies _2

Commitment and Contingencies - Lease Costs (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating lease cost	$ 1.1	$ 0.3
Weighted-average remaining lease term (in months)	43 months	27 months
Weighted-average discount rate	11.36%	11.39%

Commitment and Contingencies _3

Commitment and Contingencies - Operating Lease Schedule of Maturity (Details) - USD ($) $ in Millions	Mar. 31, 2022	Mar. 09, 2022
Commitments and Contingencies Disclosure [Abstract]
Remaining 2022	$ 3.4
2023	3.8
2024	2.8
2025	2.9
2026	2.5
Total future lease payments	15.4	$ 15
Less: imputed interest	(3)
Present value of future lease payments	$ 12.4

Commitment and Contingencies _4

Commitment and Contingencies - Noncash Lease Activities (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Operating cash outflows from operating leases	$ 0.9	$ 0.3
Operating lease assets obtained in exchange for new lease liabilities	$ 9.1	$ 0.8

Preferred and Common Stock (Det

Preferred and Common Stock (Details)	3 Months Ended
Preferred and Common Stock (Details)	Mar. 31, 2022voteshares	Dec. 31, 2021shares
Class of Stock [Line Items]
Preferred stock, outstanding (in shares)	0	0
Conversion of stock (in shares)	1
Period following that a founder ceases services to the company	12 months
Common Class A
Class of Stock [Line Items]
Voting rights, votes per share \| vote	1
Conversion of stock (in shares)	1,757,980
Common Class B
Class of Stock [Line Items]
Voting rights, votes per share \| vote	10
Conversion period	10 years
Percentage of Class B represents the aggregate of Class A	0.10
Percentage of founder shares held	0.80
Common Stock, Conversion Terms, Percent of Shareholders Needed to Specity Date	66.67%

Stock-Based Compensation_ - Nar

Stock-Based Compensation - Narrative (Details) $ / shares in Units, $ in Millions	Sep. 15, 2021shares	Jul. 19, 2021installment$ / sharesshares	Jan. 29, 2021aircraftmilestoneinstallment$ / sharesshares	Feb. 28, 2022shares	Sep. 30, 2021	Aug. 31, 2021shares	Mar. 31, 2022USD ($)milestoneshares	Mar. 31, 2021USD ($)	Sep. 16, 2021tranche	Nov. 06, 2020milestone$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense \| $							$ 24.5	$ 0.9
Founder grants, vesting percentage upon achievements	25.00%
Number of conditional purchased aircraft \| aircraft			200
Option to purchase of additional aircraft \| aircraft			100
Research and development \| $							27.5	10.1
Other warrant expense \| $							0	78.2
Research and development warrant expense \| $							$ 1.2	0
FCA Italy S.p.A.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of vesting installments \| installment		2
Warrants For Collaboration Agreement With United Airlines Inc.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Class of warrant or right, vested during the period (in shares) \| shares							8,845,058
Warrants For Collaboration Agreement With United Airlines Inc. \| United Airlines Inc.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants, issued or issuable (in shares) \| shares			14,741,764
Warrants price per share (in dollars per share) \| $ / shares			$ 0.01
Number of vesting installments \| installment			4
Number of vesting milestones \| milestone			4
Warrants For Collaboration Agreement With FCA US LLC \| FCA US LLC
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants price per share (in dollars per share) \| $ / shares										$ 0.01
Research and development \| $							$ 0.1	0.1
Number of vesting milestones \| milestone							5			7
Class of warrant or right, vested during the period (in shares) \| shares							1,236,690
Number of securities called by warrants or rights (in shares) \| shares										1,671,202
Warrants For Collaboration Agreement With FCA Italy S.p.A \| FCA Italy S.p.A.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants price per share (in dollars per share) \| $ / shares		$ 0.01
Number of securities called by warrants or rights (in shares) \| shares		1,077,024
Related service period		12 months
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense \| $							$ 19.1	0.2
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense \| $							5.4	0.7
Research and development \| Warrants For Collaboration Agreement With FCA Italy S.p.A
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Research and development warrant expense \| $							1.2
Options to purchase common stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense \| $							1	0.9
Unvested stock options \| $							$ 12.7
Weighted-average period							1 year 3 months 18 days
Unvested restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of annual bonus target amount							25.00%
Total stock-based compensation expense \| $							$ 5.7	$ 0.1
Weighted-average period							2 years 3 months 18 days
Granted (in shares) \| shares	20,009,224						1,462,209
Holders ownership once grants are fully vested	18.00%
Milestone achievement period	7 years
Founder grants, number of tranches \| tranche									4
Vested (in shares) \| shares							300,014
Share-based payment arrangement, nonvested award, cost not yet recognized, amount \| $							$ 300.1
Unvested restricted stock units \| General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense \| $							16
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percentage of outstanding stock maximum						1.00%
Purchase price of common stock, percent						85.00%
Number of shares authorized (in shares) \| shares						4,969,059
Number of additional shares authorized (in shares) \| shares						9,938,118
2021 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Conversion ratio				1
2021 Stock Plan \| Cliff Vesting
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)				1 year
2021 Stock Plan \| Unvested restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares) \| shares				1,462,209
2021 Stock Plan \| Unvested restricted stock units \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)				3 years
Award vesting rights, percentage				25.00%
2021 Stock Plan \| Unvested restricted stock units \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period (in years)				4 years
Award vesting rights, percentage				33.00%
Quarterly Equity Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense \| $							$ 1.8
Common Class A \| Warrants For Collaboration Agreement With United Airlines Inc. \| United Airlines Inc.
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of securities called by each warrant or right (in shares) \| shares			1
Common Class A \| 2021 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Capital shares reserved for future issuance (in shares) \| shares						7,453,588	3,255,791
Percentage of outstanding stock maximum					2.00%
Common Class A \| 2021 Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Capital shares reserved for future issuance (in shares) \| shares							1,627,895
Common Class B \| Unvested restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested (in shares) \| shares							5,002,306

Stock-Based Compensation_ - Sha

Stock-Based Compensation - Share-based Payment Arrangement, Option, Activity (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Number of Shares
Outstanding period start (in shares)	9,444,221
Exercised (in shares)	(753,261)
Expired/forfeited (in shares)	(86,324)
Outstanding period end (in shares)	8,604,636	9,444,221
Exercisable, Number of options (in shares)	952,603
Vested and expected to vest (in shares)	8,604,636
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 0.12
Exercise (in dollars per share)	0.12
Expired/forfeited (in dollars per share)	0.13
Ending balance (in dollars per share)	0.12	$ 0.12
Exercisable, Weighted average exercise price per share (in dollars per share)	0.12
Vested and expected to vest (in dollars per share)	$ 0.12
Weighted Average Remaining Contractual Life (Years)
Weighted average remaining contractual life (in years)	8 years 4 months 28 days	8 years 7 months 28 days
Exercisable, weighted average remaining contractual term (in years)	8 years 3 months 18 days
Vested and expected, weighted average remaining contractual term (in years)	8 years 4 months 28 days
Aggregate Intrinsic Value (In millions)
Beginning balance	$ 55.9
Exercised, aggregate intrinsic value	2.7
Ending balance	40.4	$ 55.9
Exercisable, aggregate intrinsic value	4.5
Vested and expected, aggregate intrinsic value	$ 40.4

Stock-Based Compensation_ - Res

Stock-Based Compensation - Restricted stock activity (Details) - Unvested restricted stock units - $ / shares	Sep. 15, 2021	Mar. 31, 2022
Number of Shares [Abstract]
Beginning balance (in shares)		36,249,396
Granted (in shares)	20,009,224	1,462,209
Vested (in shares)		(300,014)
Forfeited (in shares)		(624,223)
Ending balance (in shares)		36,787,368
Weighted Average Grant Price [Abstract]
Beginning balance (in dollars per share)		$ 6.53
Granted (in dollars per share)		3.06
Vested (in dollars per share)		5.07
Forfeited (in dollars per share)		7.19
Ending balance (in dollars per share)		$ 6.39

Stock-Based Compensation_ - Sto

Stock-Based Compensation - Stock-based compensation expense included in respective expense category (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 24.5	$ 0.9
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	5.4	0.7
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 19.1	$ 0.2

Stock-Based Compensation_ - Sch

Stock-Based Compensation - Schedule of Share-based Compensation, Warrant Activity (Details) - Warrants - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Number of Shares
Beginning balance (in shares)	8,644,932
Issued (in shares)	0
Exercised (in shares)	0
Ending balance (in shares)	8,644,932	8,644,932
Vested and exercisable (in shares)	1,775,202
Weighted Average Exercise Price
Beginning balance (in dollars per share)	$ 0.01
Issued (in dollars per share)	0
Exercised (in dollars per share)	0
Ending balance (in dollars per share)	0.01	$ 0.01
Vested and exercisable (in dollars per share)	$ 0.01
Weighted Average Remaining Contractual Life (Years)
Outstanding (in years)	8 years 10 months 13 days	8 years 10 months 13 days
Vested and exercisable (in years)	3 years 9 months 25 days
Aggregate Intrinsic Value (In millions)
Outstanding at period start	$ 52,100,000
Exercised	0
Outstanding at period end	52,100,000	$ 52,100,000
Vested and exercisable	$ 8,500,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended
Income Taxes (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Mar. 31, 2021
Income Tax Disclosure [Abstract]
Income tax expense	$ 0	$ 100
Effective income tax rate percent	0.00%	0.00%

401(k) Savings Plan_ (Details)

401(k) Savings Plan (Details) - USD ($) $ in Millions	3 Months Ended
401(k) Savings Plan (Details) - USD ($) $ in Millions	Mar. 31, 2022	Mar. 31, 2021
Retirement Benefits [Abstract]
Employer matching contribution, percent of match	50.00%
Defined contribution plan, cost	$ 0.5	$ 0.1

Liability Classified Warrants (

Liability Classified Warrants (Details)	3 Months Ended
Liability Classified Warrants (Details)	Mar. 31, 2022d$ / sharesshares	Sep. 16, 2021$ / sharesshares
Public Warrants
Class of Warrant or Right [Line Items]
Warrant outstanding (in shares) \| shares	17,398,947
Exercisable term from closing of initial public offering	12 months
Warrants outstanding, term	5 years
Redemption price of warrants (in dollars per share) \| $ / shares	$ 0.01	$ 11.50
Redemption period	30 days
Warrant redemption condition minimum share price (in dollars per share) \| $ / shares	$ 18
Threshold trading days \| d	20
Threshold consecutive trading days \| d	30
Threshold number of business days before sending notice of redemption to warrant holders \| d	3
Number of securities called by each warrant or right (in shares) \| shares		1
Private Placement Warrants
Class of Warrant or Right [Line Items]
Warrant outstanding (in shares) \| shares	8,000,000
Exercisable term after business combination	30 days

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event - Employee Severance	Apr. 18, 2022USD ($)
Subsequent Event [Line Items]
Capital stock transfer lock-up period with executive officer	12 months
Severance costs	$ 600,000
Severance continuance period	24 months
COBRA premium	$ 64,602.48
Accelerated vesting period	24 months
Continued vesting period	15 months
Additional payment cost	$ 1,500,000